Forte Biosciences, Inc. (FBRX): Price and Financial Metrics

Forte Biosciences, Inc. (FBRX): $0.72

0.00 (0.46%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add FBRX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#177 of 386

in industry

FBRX Price/Volume Stats

Current price $0.72 52-week high $1.15
Prev. close $0.72 52-week low $0.38
Day low $0.70 Volume 22,108
Day high $0.72 Avg. volume 33,991
50-day MA $0.68 Dividend yield N/A
200-day MA $0.72 Market Cap 26.32M

FBRX Stock Price Chart Interactive Chart >


Forte Biosciences, Inc. (FBRX) Company Bio


Forte Biosciences Inc. operates as a clinical-stage dermatology company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company is based in Torrance, California.


FBRX Latest News Stream


Event/Time News Detail
Loading, please wait...

FBRX Latest Social Stream


Loading social stream, please wait...

View Full FBRX Social Stream

Latest FBRX News From Around the Web

Below are the latest news stories about FORTE BIOSCIENCES INC that investors may wish to consider to help them evaluate FBRX as an investment opportunity.

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS, December 01, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.

Yahoo | December 1, 2023

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

DALLAS, November 13, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update.

Yahoo | November 13, 2023

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual Meeting

NEW YORK, September 14, 2023--Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we"), which collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co., LLC ("Gla

Yahoo | September 14, 2023

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s Boardroom

NEW YORK, September 06, 2023--Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we") collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"). Today, the Group and its independent director candidates – Michael Hacke and Chris McIntyre – responded to misrepresentations and distortions included

Yahoo | September 6, 2023

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

NEW YORK, August 25, 2023--Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we"), who collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today announced that they have filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with Fo

Yahoo | August 25, 2023

Read More 'FBRX' Stories Here

FBRX Price Returns

1-mo 11.11%
3-mo -2.70%
6-mo 26.25%
1-year -35.14%
3-year -87.53%
5-year -97.19%
YTD -12.38%
2023 -17.83%
2022 -53.27%
2021 -64.73%
2020 355.24%
2019 -93.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!